92 related articles for article (PubMed ID: 30223804)
1. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia.
Achtyes E; Simmons A; Skabeev A; Levy N; Jiang Y; Marcy P; Weiden PJ
BMC Psychiatry; 2018 Sep; 18(1):292. PubMed ID: 30223804
[TBL] [Abstract][Full Text] [Related]
2. What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication.
Wykes T; Evans J; Paton C; Barnes TRE; Taylor D; Bentall R; Dalton B; Ruffell T; Rose D; Vitoratou S
Psychol Med; 2017 Oct; 47(13):2369-2378. PubMed ID: 28420450
[TBL] [Abstract][Full Text] [Related]
3. Community adherence to schizophrenia treatment and safety monitoring guidelines.
Keller WR; Fischer BA; McMahon R; Meyer W; Blake M; Buchanan RW
J Nerv Ment Dis; 2014 Jan; 202(1):6-12. PubMed ID: 24375205
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study.
Wubeshet YS; Mohammed OS; Desse TA
BMC Psychiatry; 2019 Jan; 19(1):32. PubMed ID: 30658604
[TBL] [Abstract][Full Text] [Related]
5. Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders.
Gao YN; Wang R; Gu G; Chung R; Olfson M
Schizophr Res; 2024 May; 267():165-172. PubMed ID: 38547719
[TBL] [Abstract][Full Text] [Related]
6. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey.
Tandon R; Lenderking WR; Weiss C; Shalhoub H; Barbosa CD; Chen J; Greene M; Meehan SR; Duvold LB; Arango C; Agid O; Castle D
Ann Gen Psychiatry; 2020; 19():42. PubMed ID: 32684942
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.
Swanson JW; Swartz MS; Van Dorn RA; Volavka J; Monahan J; Stroup TS; McEvoy JP; Wagner HR; Elbogen EB; Lieberman JA;
Br J Psychiatry; 2008 Jul; 193(1):37-43. PubMed ID: 18700216
[TBL] [Abstract][Full Text] [Related]
8. Secondary effects of antipsychotics: women at greater risk than men.
Seeman MV
Schizophr Bull; 2009 Sep; 35(5):937-48. PubMed ID: 18400811
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in schizophrenia.
McCabe R; Saidi M; Priebe S
Br J Psychiatry Suppl; 2007 Aug; 50():s21-8. PubMed ID: 18019040
[TBL] [Abstract][Full Text] [Related]
10. Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan.
Sugawara N; Ishioka M; Tsuchimine S; Tsuruga K; Sato Y; Furukori H; Kudo S; Tomita T; Nakagami T; Yasui-Furukori N
PLoS One; 2015; 10(11):e0143356. PubMed ID: 26600382
[TBL] [Abstract][Full Text] [Related]
11. The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.
Libowitz MR; Nurmi EL
Front Psychiatry; 2021; 12():623681. PubMed ID: 33776816
[TBL] [Abstract][Full Text] [Related]
12. Partial Personalization of Medical Treatment Decisions: Adverse Effects and Possible Solutions.
Weyant C; Brandeau ML
Med Decis Making; 2022 Jan; 42(1):8-16. PubMed ID: 34027738
[TBL] [Abstract][Full Text] [Related]
13. Awakening on antipsychotic medication: A call to action.
Deegan PE; Stiles A; Rufo M; Zisman-Ilani Y
Psychiatr Rehabil J; 2024 Apr; ():. PubMed ID: 38573672
[TBL] [Abstract][Full Text] [Related]
14. Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness.
Lang DJ; Barr AM; Procyshyn RM
Curr Cardiovasc Risk Rep; 2013 Aug; 7(4):283-287. PubMed ID: 23864926
[TBL] [Abstract][Full Text] [Related]
15. Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.
Shrivastava A; Johnston ME
Mens Sana Monogr; 2010 Jan; 8(1):53-68. PubMed ID: 21327170
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients.
Suda A; Hattori S; Kishida I; Miyauchi M; Shiraishi Y; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Hirayasu Y
Neuropsychiatr Dis Treat; 2018; 14():2361-2366. PubMed ID: 30271152
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis.
Krause M; Huhn M; Schneider-Thoma J; Rothe P; Smith RC; Leucht S
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1360-1370. PubMed ID: 30243680
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps.
Jeun KJ; Kamal KM; Adhikari K; Nolfi DA; Ashraf MN; Zacker C
J Manag Care Spec Pharm; 2024 Feb; 30(2):183-199. PubMed ID: 38308625
[TBL] [Abstract][Full Text] [Related]
19. Patient's Perspective on Psychiatric Drugs: A Multicenter Survey-Based Study.
Han S; Kim SY; Jung YE; Kim W; Seo JS; Sohn I; Lee K; Lee JH; Chung SK; Lee SY; Hong JW; Yoon BH; Woo YS; Han C; Chang JG; Bahk WM; Song HR; Hong M
Psychiatry Investig; 2024 Jan; 21(1):28-36. PubMed ID: 38114066
[TBL] [Abstract][Full Text] [Related]
20. An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs.
Chow RTS; Whiting D; Favril L; Ostinelli E; Cipriani A; Fazel S
Neurosci Biobehav Rev; 2023 Dec; 155():105454. PubMed ID: 37925094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
